Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...

The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann Purchase Licensing Rights, opens new tab ...

Exforge Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure - Exforge offers two of the most prescribed high blood pressure medicines in a ...

Novartis' blood pressure drug Exforge -- a combination of the Swiss drugmaker's Diovan and the generic form of Pfizer's Norvasc -- performed better than Norvasc alone, according to a newly ...

Exforge HCT contains the active ingredients, amlodipine besilate, valsartan and hydrochlorothiazide. Exforge HCT belongs to a group of medicines called antihypertensives. These medicines help ...

Exforge is a combination of two blood pressure blockbusters: Diovan from Novartis (down $0.38 to $55.14, Charts), which totaled $4.2 billion in 2006 sales, and Pfizer's Norvasc.